, Les laboratoires A et B n'ont transmis aucune information pour des raisons de confidentialité

, Les résultats détaillés ci-dessous sont uniquement issus des réponses des pharmaciens

E. France, 10 établissements de santé au total (8 CHU et 2 CLCC) peuvent prescrire des médicaments CAR-T : Hôpital Saint-Louis

, Sur l'ensemble des établissements de santé français, 25% des CHU et 11% des CLCC sont qualifiés (figures 27 et 28)

. Actuellement, 7 autres établissements, 6 CHU et 1 CLCC, sont en cours de qualification

. Inca, Les cancers en France en 2018 -L'essentiel des faits et chiffres (édition 2019, 2019.

M. M. Boyiadzis, M. V. Dhodapkar, R. J. Brentjens, J. N. Kochenderfer, S. S. Neelapu et al., Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance, J Immunother Cancer. 4 déc, vol.6, issue.1, p.137, 2018.

S. L. Maude, D. T. Teachey, D. L. Porter, and S. A. Grupp, CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia, Blood. 25 juin, vol.125, issue.26, pp.4017-4040, 2015.

, Collège des Enseignants d'Immunologie. Immunologie fondamentale et immunopathologie. 2ème édition, vol.344, 2018.

V. Catros-quemener, F. Bouet, and N. Genetet, Antitumor immunity and cellular cancer therapies, Med Sci (Paris). janv, vol.19, issue.1, pp.43-53, 2003.

M. Rubio, J. Galaine, C. Borg, É. Daguindau, and . Biologie, concepts et principes des CAR-T cells, vol.105, pp.135-181, 2018.

C. Zhang, J. Liu, J. F. Zhong, and X. Zhang, Engineering CAR-T cells, Biomark Res, vol.5, p.22, 2017.

H. Dai, Y. Wang, X. Lu, and W. Han, Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy, J Natl Cancer Inst. juill, vol.108, issue.7, 2016.

M. Cartellieri, M. Bachmann, A. Feldmann, C. Bippes, S. Stamova et al., Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer, Journal of Biomedicine and Biotechnology, vol.2010, pp.1-13, 2010.

Y. Leyfman, Chimeric antigen receptors: unleashing a new age of anti-cancer therapy, Cancer Cell Int, vol.18, p.182, 2018.

S. Farkona, E. P. Diamandis, and I. M. Blasutig, Cancer immunotherapy: the beginning of the end of cancer, BMC Med. 5 mai, vol.14, p.73, 2016.

Z. Eshhar, T. Waks, G. Gross, and D. G. Schindler, Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc Natl Acad Sci, vol.15, issue.2, pp.720-724, 1993.

Z. Eshhar, G. Gross, T. Waks, J. Lustgarten, N. Bach et al., Chimeric T-Cell Receptors with Antibody-Type Specificity. Methods, vol.8, issue.2, pp.133-175, 1995.

S. S. Neelapu, F. L. Locke, N. L. Bartlett, L. J. Lekakis, D. B. Miklos et al., Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N Engl J Med, vol.28, issue.26, pp.2531-2575, 2017.

S. L. Maude, T. W. Laetsch, J. Buechner, S. Rives, M. Boyer et al., Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N Engl J Med, vol.01, issue.5, pp.439-487, 2018.

S. J. Schuster, M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann et al., Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma, N Engl J Med. 3 janv, vol.380, issue.1, pp.45-56, 2019.

Z. Zhao, M. Condomines, S. Van-der-stegen, F. Perna, C. C. Kloss et al., Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells, Cancer Cell, vol.28, issue.4, pp.415-443, 2015.

E. Kymriah, RCP

D. Sur,

E. Yescarta, RCP

D. Sur,

X. Zhong, M. Matsushita, J. Plotkin, I. Riviere, and M. Sadelain, Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cellmediated tumor eradication, Mol Ther. févr, vol.18, issue.2, pp.413-433, 2010.

M. Chmielewski and H. Abken, TRUCKs: the fourth generation of CARs, Expert Opin Biol Ther, vol.15, issue.8, pp.1145-54, 2015.

L. Zhang, R. A. Morgan, J. D. Beane, Z. Zheng, M. E. Dudley et al., Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma, Clin Cancer Res. 15 mai, vol.21, issue.10, pp.2278-88, 2015.

. Inca, Les immunothérapies spécifiques dans le traitement des cancers -Rapport, 2018.

S. Vairy, J. L. Garcia, P. Teira, and H. Bittencourt, CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia, Drug Des Devel Ther, vol.12, pp.3885-98, 2018.

B. L. Levine, J. Miskin, K. Wonnacott, and C. Keir, Global Manufacturing of CAR T Cell Therapy, Mol Ther Methods Clin Dev. 17 mars, vol.4, pp.92-101, 2017.

H. Singh, H. Huls, and L. J. Cooper, A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19, Immunological reviews. janv, vol.257, issue.1, p.181, 2014.

R. Monjezi, C. Miskey, T. Gogishvili, M. Schleef, M. Schmeer et al., Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors, Leukemia, vol.31, issue.1, pp.186-94, 2017.

P. Kebriaei, H. Singh, M. H. Huls, M. J. Figliola, R. Bassett et al., Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells, J Clin Invest, vol.01, issue.9, pp.3363-76, 2016.

. Société-française-d'hématologie and . Hématologie, Chapitre 4: Item 312 -UE 9 Leucémies aiguës

, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, p.96, 2014.

C. Pui, J. J. Yang, S. P. Hunger, R. Pieters, M. Schrappe et al., Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration, J Clin Oncol. 20 sept, vol.33, issue.27, pp.2938-2986, 2015.

F. Huguet, S. Chevret, T. Leguay, X. Thomas, N. Boissel et al., Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial, J Clin Oncol. 20 août, vol.36, issue.24, pp.2514-2537, 2018.

. Has, . Avis, and . Kymriah,

D. Sur,

P. S. Gaynon, Childhood acute lymphoblastic leukaemia and relapse, British Journal of Haematology, vol.131, issue.5, pp.579-87, 2005.

. Novartis, Résumé du rapport périodique de synthèse de Kymriah

D. Sur,

. Société-française-d'hématologie and . Hématologie, Chapitre 12: Item 316 -UE 9 Lymphomes malins

, ALD n° 30 -Lymphomes non hodgkiniens de l'adulte, HAS

H. Autorité-de-santé,

S. Ouassou, L. Herrak, L. Achachi, F. Nachite, K. Znati et al., Lymphome B à grandes cellules primitif du médiastin chez la femme: à propos de cinq cas, Pan Afr Med J, vol.30, issue.2016

, Lymphome médiastinal primitif à grandes cellules B

. Has, . Avis, and . Yescarta,

D. Sur,

. Has, . Avis, and . Kymriah,

H. Autorité-de-santé,

S. S. Neelapu, F. L. Locke, N. L. Bartlett, L. J. Lekakis, D. B. Miklos et al., Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N Engl J Med. 28 déc, vol.377, issue.26, pp.2531-2575, 2017.

. Gilead, Résumé du rapport périodique de synthèse de Yescarta

D. Sur,

T. Lamy-de-la-chapelle, . Car-t, and . Ldgcb, données générales en vraie vie, résultats et facteurs prédictifs de toxicité -Congrès ASH 2018, 2018.

J. N. Brudno and J. N. Kochenderfer, Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management, Blood Rev, vol.34, pp.45-55, 2019.

C. J. Turtle, L. Hanafi, C. Berger, T. A. Gooley, S. Cherian et al., CD19 CAR-T cells of defined CD4 + :CD8 + composition in adult B cell ALL patients, J Clin Invest. 1 juin, vol.126, issue.6, pp.2123-2161, 2016.

D. W. Lee, R. Gardner, D. L. Porter, C. U. Louis, N. Ahmed et al., Current concepts in the diagnosis and management of cytokine release syndrome, Blood. 10 juill, vol.124, issue.2, pp.188-95, 2014.

P. J. Bugelski, R. Achuthanandam, R. J. Capocasale, G. Treacy, and E. Bouman-thio, Monoclonal antibodyinduced cytokine-release syndrome, Expert Review of Clinical Immunology. 1 sept, vol.5, issue.5, pp.499-521, 2009.

M. C. Panelli, R. White, M. Foster, B. Martin, W. E. Smith et al., Forecasting the cytokine storm following systemic interleukin (IL)-2 administration, Journal of Translational Medicine, vol.2, p.17, 2004.

N. V. Frey and D. L. Porter, Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia, Hematology. 12 févr, vol.2016, issue.1, pp.567-72, 2016.

J. N. Brudno and J. N. Kochenderfer, Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, vol.30, issue.26, pp.3321-3351, 2016.

C. L. Bonifant, H. J. Jackson, R. J. Brentjens, and K. J. Curran, Toxicity and management in CAR T-cell therapy, Mol Ther Oncolytics, vol.3, p.16011, 2016.

S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett et al., Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, vol.371, issue.16, pp.1507-1524, 2014.

K. A. Hay, L. Hanafi, D. Li, J. Gust, W. C. Liles et al., Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy, Blood, vol.130, issue.21, pp.2295-306, 2017.

E. Roactemra, RCP

D. Sur,

S. A. Grupp, M. Kalos, D. Barrett, R. Aplenc, D. L. Porter et al., Chimeric antigen receptormodified T cells for acute lymphoid leukemia, N Engl J Med. 18 avr, vol.368, issue.16, pp.1509-1527, 2013.

. Has, . Avis, and . Roactemra,

D. Sur,

L. L. Riegler, G. P. Jones, and D. W. Lee, Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy, Ther Clin Risk Manag. 28 févr, vol.15, pp.323-358, 2019.

N. V. Frey, B. L. Levine, S. F. Lacey, S. A. Grupp, S. L. Maude et al., Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells, Blood. 6 déc, vol.124, issue.21, pp.2296-2296, 2014.

. Medscape, CAR T-Cell Leukemia Trial Put on Hold After Two Deaths

D. Sur,

C. J. Turtle, K. A. Hay, L. Hanafi, D. Li, S. Cherian et al., Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib, JCO. 17 juill, vol.35, issue.26, pp.3010-3030, 2017.

S. S. Neelapu, S. Tummala, P. Kebriaei, W. Wierda, C. Gutierrez et al., Chimeric antigen receptor T-cell therapy -assessment and management of toxicities, Nat Rev Clin Oncol. janv, vol.15, issue.1, pp.47-62, 2018.

S. L. Maude, N. Frey, P. A. Shaw, R. Aplenc, D. M. Barrett et al., Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med, vol.371, issue.16, pp.1507-1524, 2014.

J. Gust, K. A. Hay, L. Hanafi, D. Li, D. Myerson et al., Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells, Cancer Discov, vol.7, issue.12, pp.1404-1423, 2017.

. Clinicaltrials,

D. Sur, Société française d'Hématologie. Hématologie, Chapitre 8: Item 315 -UE 9 Leucémie lymphoïde chronique

D. L. Porter, W. Hwang, N. V. Frey, S. F. Lacey, P. A. Shaw et al., Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci Transl Med. 2 sept, vol.7, issue.303, pp.303-139, 2015.

E. Imbruvica, RCP

D. Sur,

S. Gill, N. V. Frey, E. O. Hexner, S. F. Lacey, J. J. Melenhorst et al., CD19 CAR-T cells combined with ibrutinib to induce complete remission in CLL, vol.35, pp.7509-7509, 2017.

M. Dourthe, K. Yakouben, D. Chaillou, E. Lesprit, J. Dalle et al., CAR-T cells : indications actuelles en pédiatrie et perspectives de développement, Bulletin du Cancer. déc, vol.105, pp.147-57, 2018.

N. N. Shah, M. Stetler-stevenson, C. M. Yuan, K. Richards, C. Delbrook et al., Characterization of CD22 Expression in Acute Lymphoblastic Leukemia, Pediatr Blood Cancer. juin, vol.62, issue.6, pp.964-973, 2015.

W. Haso, D. W. Lee, N. N. Shah, M. Stetler-stevenson, C. M. Yuan et al., Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia, Blood. 14 févr, vol.121, issue.7, pp.1165-74, 2013.

B. G. Till, M. C. Jensen, J. Wang, E. Y. Chen, B. L. Wood et al., Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood. 15 sept, vol.112, issue.6, pp.2261-71, 2008.

M. Mamonkin, R. H. Rouce, H. Tashiro, and M. K. Brenner, A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies, Blood. 20 août, vol.126, issue.8, pp.983-92, 2015.

D. Gomes-silva, M. Srinivasan, S. Sharma, C. M. Lee, D. L. Wagner et al., CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies, Blood, vol.20, issue.3, pp.285-96, 2017.

S. S. Kenderian, M. Ruella, O. Shestova, M. Klichinsky, V. Aikawa et al., CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia, Leukemia. août, vol.29, issue.8, pp.1637-1684, 2015.

M. Cartellieri, A. Feldmann, S. Koristka, C. Arndt, S. Loff et al., Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts, Blood Cancer J. août, vol.6, issue.8, p.458, 2016.

D. A. Sallman, J. Brayer, E. M. Sagatys, C. Lonez, E. Breman et al., NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient, Haematologica, vol.103, issue.9, pp.424-430, 2018.

. Société-française-d'hématologie and . Hématologie, Item 317 -UE 9 Myélome multiple, vol.9

R. O. Carpenter, M. O. Evbuomwan, S. Pittaluga, J. J. Rose, M. Raffeld et al., B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma, Clin Cancer Res. 15 avr, vol.19, issue.8, pp.2048-60, 2013.

S. A. Ali, V. Shi, I. Maric, M. Wang, D. F. Stroncek et al., T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma, Blood, vol.29, issue.13, pp.1688-700, 2016.

N. Raje, J. Berdeja, Y. Lin, D. Siegel, S. Jagannath et al., Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma, N Engl J Med. 2 mai, vol.380, issue.18, pp.1726-1763, 2019.

T. Gogishvili, S. Danhof, S. Prommersberger, J. Rydzek, M. Schreder et al., SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7 + normal lymphocytes, Blood. 28 déc, vol.130, issue.26, pp.2838-2885, 2017.

S. C. Katz, R. A. Burga, E. Mccormack, L. J. Wang, W. Mooring et al., Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases, Clin Cancer Res. 15 juill, vol.21, issue.14, pp.3149-59, 2015.

C. Zhang, Z. Wang, Z. Yang, M. Wang, S. Li et al., Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers, Mol Ther, vol.03, issue.5, pp.1248-58, 2017.

J. L. Tanyi, A. R. Haas, G. L. Beatty, C. J. Stashwick, M. H. O'hara et al., Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer, JCO. 20 mai, vol.34, issue.15_suppl, pp.5511-5511, 2016.

Y. Guo, K. Feng, Y. Liu, Z. Wu, H. Dai et al., Phase I Study of Chimeric Antigen ReceptorModified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers, Clin Cancer Res, vol.15, issue.6, pp.1277-86, 2018.

K. Feng, Y. Guo, H. Dai, Y. Wang, X. Li et al., Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer, Sci China Life Sci. mai, vol.59, issue.5, pp.468-79, 2016.

R. P. Junghans, Q. Ma, R. Rathore, E. M. Gomes, A. J. Bais et al., Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response, Prostate, vol.76, issue.14, pp.1257-70, 2016.

C. U. Louis, B. Savoldo, G. Dotti, M. Pule, E. Yvon et al., Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma, Blood. 1 déc, vol.118, issue.23, pp.6050-6056, 2011.

C. E. Brown, D. Alizadeh, R. Starr, L. Weng, J. R. Wagner et al., Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy, N Engl J Med, vol.29, issue.26, pp.2561-2570, 2016.

V. Alcazer, C. Delenda, L. Poirot, and S. Depil, Développement des CAR-T dans les tumeurs solides, Bulletin du Cancer. déc, vol.105, pp.178-87, 2018.

T. R. Baybutt, J. C. Flickinger, E. M. Caparosa, and A. E. Snook, Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors, Clin Pharmacol Ther. janv, vol.105, issue.1, pp.71-79, 2019.

K. T. Roybal, L. J. Rupp, L. Morsut, W. J. Walker, K. A. Mcnally et al., Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell. 11 févr, vol.164, issue.4, pp.770-779, 2016.

M. M. Boyiadzis, M. V. Dhodapkar, R. J. Brentjens, J. N. Kochenderfer, S. S. Neelapu et al., Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance, J Immunother Cancer. 4 déc, vol.6, issue.1, p.137, 2018.

Y. Yang, E. Jacoby, and T. J. Fry, Challenges and opportunities of allogeneic donor-derived CAR T cells: Current Opinion in Hematology, vol.22, pp.509-524, 2015.

, Directive 2003/63/CE de la Commission, du 25 juin 2003, modifiant la directive 2001/83/CE du Parlement européen et du Conseil instituant un code communautaire relatif aux médicaments à usage humain, vol.27, 2003.

. Règlement, 1394/2007 du Parlement européen et du Conseil du 13 novembre 2007 concernant les médicaments de thérapie innovante et modifiant la directive 2001/83/CE ainsi que le règlement (CE), vol.726, 2004.

. Oj-l, Directive 2004/23/CE du Parlement européen et du Conseil du 31 mars 2004 relative à l'établissement de normes de qualité et de sécurité pour le don, l'obtention, le contrôle, la transformation, la conservation, le stockage et la distribution des tissus et cellules humains, 2007.

A. Guide, Médicaments de thérapie innovante préparé ponctuellement et préparations : Synthèse du cadre réglementaire applicable pour la fabrication, le développement et la mise sur le marché de ces produits, ANSM : Médicaments de thérapie innovante, 2012.

D. Sur,

, Public Health -European Commission. Community Register of orphan medicinal products

, Union Register of medicinal products

. Ansm, Décision d'autorisation de la mise sur le marché d'organismes génétiquement modifiés dans le cadre d'une autorisation temporaire d'utilisation portant sur un médicament à usage humain -KYMRIAH (Tisagenlecleucel), 2018.

C. Chabannon and J. Larghero, Prise en charge des cellules CAR-T au sein des établis-sements de santé français : fabrication, distribution, et aspects réglementaires. Bulletin de l'Académie Nationale de Médecine, sept, vol.202, issue.7, pp.1431-1471, 2018.

A. European-medicines, PRIME: priority medicines, 2018.

D. Sur,

D. Seimetz, K. Heller, and J. Richter, Approval of First CAR-Ts: Have we Solved all Hurdles for ATMPs?, Cell Med. janv, vol.11, p.215517901882278, 2019.

. Jorf, Arrêté du 28 mars 2019 limitant l'utilisation de médicament de thérapie innovante à base de lymphocytes T génétiquement modifiés dits CAR-T Cells autologues indiqués dans le traitement de la leucémie aiguë lymphoblastique à cellules B et/ou du lymphome à grande cellule B, à certains établissements de santé en application des dispositions de l'article L. 1151-1 du code de la santé publique, vol.10, 2019.

. Jorf, Arrêté du 8 août 2019 modifiant l'arrêté du 28 mars 2019 limitant l'utilisation de médicament de thérapie innovante à base de lymphocytes T génétiquement modifiés dits CAR-T Cells autologues indiqués dans le traitement de la leucémie aiguë lymphoblastique à cellules B et/ou du lymphome à grande cellule B, à certains établissements de santé en application des

, HAS. Avis d'efficience YESCARTA (axicabtagene ciloleucel), CAR T anti-CD19, 2019.

J. , Avis relatif aux prix de spécialités pharmaceutiques publiés en application de l'article L. 162-16-6 du code de la sécurité sociale, vol.13, 2019.

, HAS. Avis d'efficience KYMRIAH (tisagenlecleucel), CAR T anti-CD19, 2019.

, HAS. Avis d'efficience KYMRIAH (tisagenlecleucel), CAR T anti-CD19 (LDGCB), 2019.

M. Médecins-du, Notre opposition au brevet Kymriah®

A. , Notice technique n° 2-790-2019 du 24 décembre 2018-PMSI 2019

, ATIH. Notice technique n° ATIH-371-6-2019 du 22 juillet 2019 -Nouveaux recueils Traitements de type CAR-T cells, 2019.

C. Chabannon and J. Larghero, Prise en charge des cellules CAR-T au sein des établis-sements de santé français : fabrication, distribution, et aspects réglementaires

. Em-consulte,

D. Sur,